Utilization of Antitumor Necrosis Factor Biologics in Very Early Onset Inflammatory Bowel Disease: A Multicenter Retrospective Cohort Study From North America
- Kerur, Basavaraj
- Fiedler, Karoline
- Stahl, Marisa
- Hyams, Jeffrey
- Stephens, Michael
- Lu, Ying
- Pfefferkorn, Marian
- Alkhouri, Raza
- Strople, Jennifer
- Kelsen, Judith
- Siebold, Leah
- Goyal, Alka
- Rosh, Joel R.
- LeLeiko, Neal
- van Limbergen, Johan
- Guerrerio, Anthony L.
- Maltz, Ross M.
- Karam, Lina
- Crowley, Eileen
- Griffiths, Anne M.
- Heyman, Melvin B.
- Deneau, Mark
- Benkov, Keith
- Noe, Joshua
- Moulton, Dedrick
- Pappa, Helen
- Galanko, Joseph
- Snapper, Scott
- Muise, Aleixo M.
- Kappelman, Michael D.
- Benchimol, Eric I.
DOIAbstract
BACKGROUND: Research on the utilization and effectiveness of antitumor necrosis factor (TNF) biologics in children with very early onset inflammatory bowel disease (VEOIBD) is urgently needed. Here we describe anti-TNF use and durability in a multicenter cohort. METHODS: We performed a retrospective cohort study of patients diagnosed with VEOIBD (<6 years) between 2008 and 2013 at 25 North American centers. We performed chart abstraction at diagnosis and 1, 3, and 5 years after diagnosis. We examined the rate of initiation and durability of infliximab and adalimumab and evaluated associations between treatment durability and the following covariates with multivariate Cox proportional hazard regression: age at diagnosis, sex, disease duratio...
Add to ORKG